Evaluation of Pain Treatment After Total Knee Arthroplasty

Purpose

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Condition

  • Pain

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m^2) - Scheduled to undergo an elective primary unilateral TKA surgery

Exclusion Criteria

  • History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Suzetrigine (SUZ) 		Participants will receive SUZ for 14 days.
  • Drug: Suzetrigine
    Tablets for oral administration.
    Other names:
    • VX-548
    • JOURNAVX
Placebo Comparator
Placebo 		Participants will receive placebo matched to SUZ for 14 days
  • Drug: Placebo
    Placebo matched to SUZ for oral administration

Recruiting Locations

Memorial Hermann Village Office
Houston, Texas 77043

More Details

Status
Recruiting
Sponsor
Vertex Pharmaceuticals Incorporated

Study Contact

Medical Information
617-341-6777
medicalinfo@vrtx.com